Baxter International Inc. BAX
23.37
(0.11)
(0.47%)
as of 25 Sep
- Market cap
- $12.2B
- P/E
- 0.0×
Follow BAX
Indexes
indicate stock being part of an index,
Growth Flags
show if company had growth for consecutive years
Baxter International Inc. (BAX) Net margin
Baxter International Inc.'s net margin over the twelve months to 30 June 2026 was −9.27%, down 0.8 percentage points from fiscal 2025 (−8.51%). Over the past ten years it has ranged from −24.2% (fiscal 2022) to 48.9% (fiscal 2016); the current reading is higher than 18% of that period. That is below the Medical Instruments & Supplies industry median of 0.00% and below the Healthcare sector median of 0.00%.
Net margin, annual
Annual
| Period | Net margin | Change (points) |
|---|---|---|
| FY2025 | −8.51% | (2.41) |
| FY2024 | −6.10% | (31.74) |
| FY2023 | 25.6% | 49.83 |
| FY2022 | −24.2% | (34.76) |
| FY2021 | 10.6% | 1.13 |
| FY2020 | 9.44% | 0.63 |
| FY2019 | 8.81% | (5.12) |
| FY2018 | 13.9% | 8.24 |
| FY2017 | 5.69% | (43.16) |
| FY2016 | 48.9% | 39.14 |
Quarterly
| Period | Net margin | Change (points) |
|---|---|---|
| Jun 2026 | 4.26% | 4.82 |
| Mar 2026 | −0.56% | 37.37 |
| Dec 2025 | −37.9% | (36.31) |
| Sep 2025 | −1.62% | (4.86) |
| 42 more quarters | Free account |
Against its own ten years
Low −24.2%
High 48.9%
Ten-year median
9.44%
Current reading's percentile
18
Net margin against peers
| Company | Net margin |
|---|---|
| SOLV Solventum Corporation compare | 17.3% |
| COO The Cooper Companies, Inc. compare | 13.5% |
| STVN Stevanato Group S.p.A. compare | 11.0% |
| ALGN Align Technology, Inc. compare | 9.99% |
| ATR AptarGroup, Inc. compare | 9.22% |
| RGEN Repligen Corporation compare | 5.29% |
| BLCO Bausch + Lomb Corporation compare | −3.21% |
| AVTR Avantor, Inc. compare | −8.81% |
| BAX Baxter International Inc. | −9.27% |
| Medical Instruments & Supplies industry median | 0.00% |
| Healthcare sector median | 0.00% |
| Market median | 0.55% |
What Net margin is
Net Profit Margin tells an investor how much of each unit of revenue ends up as profit for shareholders after all costs, interest and taxes.
Net Income Allotted to Shareholders ÷ Revenue
More on BAX
- Revenue
- Net income
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- The full statement